Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Lorenza Rimassa, S.L. Chan, Bruno Sangro, George K.K. Lau, Masatochi Kudo, Valeriy Vladimirovich Breder and 14 more
- Rank
- 89 of 3,853
- Percentile
- top 2.4%
- Where
- Annals of Oncology, 2024
- Citations
- 25
From the 2024 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.